Adobe Acrobat – 9789240093249-eng-1.pdf
View this file, and add comments too.
View this file, and add comments too.
At Merck, we’re following the science to tackle some of the world’s greatest health threats. Get a glimpse of how we work to improve lives.
Information about the artificial intelligence and bioinformatics workshop for the Early Detection Research Network, August 2024
Purpose: This study sought to describe the changes in immune response to a third dose of either Pfizer’s or Moderna’s COVID-19 mRNA vaccine (3V) among…
Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients with…
PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of…
Abstract. Background: Multiple myeloma (MM) patients are immunocompromised due to defects in humoral/cellular immunity and immunosuppressive therapy. Repor
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Secondary immunodeficiency is reported in most patients with hematological malignancies such as chronic lymphocytic leukemia and multiple myeloma. The aim of…
A tenth of patients die within 60 days of diagnosis of MM. Infection and renal failure are the main direct causes of early mortality, which…
Patients with chronic lymphocytic leukemia (CLL) have been previously shown to have poor responses to antibacterial and antiviral vaccines. In a Plenary Pa